JP2021182946A5 - - Google Patents

Download PDF

Info

Publication number
JP2021182946A5
JP2021182946A5 JP2021144677A JP2021144677A JP2021182946A5 JP 2021182946 A5 JP2021182946 A5 JP 2021182946A5 JP 2021144677 A JP2021144677 A JP 2021144677A JP 2021144677 A JP2021144677 A JP 2021144677A JP 2021182946 A5 JP2021182946 A5 JP 2021182946A5
Authority
JP
Japan
Prior art keywords
compound
compound according
composition
isobutyryl
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021144677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021182946A (ja
JP7736489B2 (ja
Filing date
Publication date
Priority claimed from JP2019234301A external-priority patent/JP2020050670A/ja
Application filed filed Critical
Publication of JP2021182946A publication Critical patent/JP2021182946A/ja
Priority to JP2022005584A priority Critical patent/JP7308309B2/ja
Publication of JP2021182946A5 publication Critical patent/JP2021182946A5/ja
Priority to JP2023060170A priority patent/JP2023073510A/ja
Application granted granted Critical
Publication of JP7736489B2 publication Critical patent/JP7736489B2/ja
Priority to JP2025188613A priority patent/JP2026016798A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021144677A 2014-05-01 2021-09-06 オリゴヌクレオチド組成物及びその作製方法 Active JP7736489B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022005584A JP7308309B2 (ja) 2014-05-01 2022-01-18 オリゴヌクレオチド組成物及びその作製方法
JP2023060170A JP2023073510A (ja) 2014-05-01 2023-04-03 オリゴヌクレオチド組成物及びその作製方法
JP2025188613A JP2026016798A (ja) 2014-05-01 2025-11-07 オリゴヌクレオチド組成物及びその作製方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US61/987,396 2014-05-01
US201562151909P 2015-04-23 2015-04-23
US62/151,909 2015-04-23
JP2019234301A JP2020050670A (ja) 2014-05-01 2019-12-25 オリゴヌクレオチド組成物及びその作製方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019234301A Division JP2020050670A (ja) 2014-05-01 2019-12-25 オリゴヌクレオチド組成物及びその作製方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022005584A Division JP7308309B2 (ja) 2014-05-01 2022-01-18 オリゴヌクレオチド組成物及びその作製方法

Publications (3)

Publication Number Publication Date
JP2021182946A JP2021182946A (ja) 2021-12-02
JP2021182946A5 true JP2021182946A5 (https=) 2022-01-26
JP7736489B2 JP7736489B2 (ja) 2025-09-09

Family

ID=54359301

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2016564990A Active JP7040892B2 (ja) 2014-05-01 2015-04-29 オリゴヌクレオチド組成物及びその作製方法
JP2018088277A Pending JP2018131453A (ja) 2014-05-01 2018-05-01 オリゴヌクレオチド組成物及びその作製方法
JP2019234301A Withdrawn JP2020050670A (ja) 2014-05-01 2019-12-25 オリゴヌクレオチド組成物及びその作製方法
JP2021144677A Active JP7736489B2 (ja) 2014-05-01 2021-09-06 オリゴヌクレオチド組成物及びその作製方法
JP2022005584A Active JP7308309B2 (ja) 2014-05-01 2022-01-18 オリゴヌクレオチド組成物及びその作製方法
JP2023060170A Withdrawn JP2023073510A (ja) 2014-05-01 2023-04-03 オリゴヌクレオチド組成物及びその作製方法
JP2025188613A Pending JP2026016798A (ja) 2014-05-01 2025-11-07 オリゴヌクレオチド組成物及びその作製方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016564990A Active JP7040892B2 (ja) 2014-05-01 2015-04-29 オリゴヌクレオチド組成物及びその作製方法
JP2018088277A Pending JP2018131453A (ja) 2014-05-01 2018-05-01 オリゴヌクレオチド組成物及びその作製方法
JP2019234301A Withdrawn JP2020050670A (ja) 2014-05-01 2019-12-25 オリゴヌクレオチド組成物及びその作製方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022005584A Active JP7308309B2 (ja) 2014-05-01 2022-01-18 オリゴヌクレオチド組成物及びその作製方法
JP2023060170A Withdrawn JP2023073510A (ja) 2014-05-01 2023-04-03 オリゴヌクレオチド組成物及びその作製方法
JP2025188613A Pending JP2026016798A (ja) 2014-05-01 2025-11-07 オリゴヌクレオチド組成物及びその作製方法

Country Status (33)

Country Link
US (6) US9796747B2 (https=)
EP (2) EP3137479B1 (https=)
JP (7) JP7040892B2 (https=)
KR (4) KR20230088509A (https=)
CN (3) CN117357548A (https=)
AP (1) AP2016009489A0 (https=)
AU (3) AU2015253158B2 (https=)
BR (1) BR112016025196B1 (https=)
CL (4) CL2016002749A1 (https=)
DK (1) DK3137479T5 (https=)
EA (1) EA034882B9 (https=)
ES (1) ES2963740T3 (https=)
FI (1) FI3137479T3 (https=)
HR (1) HRP20231505T1 (https=)
HU (1) HUE064289T2 (https=)
IL (2) IL248044B (https=)
JO (2) JOP20200257A1 (https=)
LT (1) LT3137479T (https=)
MA (1) MA63525B1 (https=)
MX (2) MX382233B (https=)
MY (2) MY178617A (https=)
PE (1) PE20170147A1 (https=)
PH (1) PH12016502080A1 (https=)
PL (1) PL3137479T3 (https=)
PT (1) PT3137479T (https=)
RS (1) RS64860B1 (https=)
SG (2) SG11201608226YA (https=)
SI (1) SI3137479T1 (https=)
SM (1) SMT202300405T1 (https=)
TW (2) TWI712413B (https=)
UA (1) UA126108C2 (https=)
WO (1) WO2015168310A1 (https=)
ZA (2) ZA201606624B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02933B (me) * 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
AU2016250576C1 (en) 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
MA49555A (fr) * 2017-07-10 2021-04-28 Geron Corp Procédé amélioré de préparation d'imetelstat
CN114901269A (zh) 2019-10-28 2022-08-12 美国杰龙生物医药公司 3-棕榈酰基-酰胺基-1,2-丙二醇和3-棕榈酰基-酰胺基-2-羟基-1-二甲氧基三苯基甲基醚-丙烷的结晶固体及其制备和使用方法
AU2020372865A1 (en) * 2019-10-28 2022-05-26 Geron Corporation Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same
KR20220123300A (ko) 2020-01-08 2022-09-06 닛토덴코 가부시키가이샤 분절-타입 아미디트(segment-type amidite)를 사용한 핵산 합성 방법
KR20240100491A (ko) 2021-10-15 2024-07-01 코덱시스, 인코포레이티드 조작된 말단 데옥시뉴클레오티딜 트랜스퍼라제 변이체
KR20250008345A (ko) 2023-07-07 2025-01-14 주식회사 엘지에너지솔루션 체결기구 및 체결기구를 포함하는 전지팩

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP0462145B1 (en) 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
CA2079109A1 (en) 1990-03-29 1991-09-30 John A. Latham Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
EP0724589B1 (en) 1993-10-18 2005-12-07 The Walter And Eliza Hall Institute Of Medical Research A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
HUT76094A (en) 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
AU696702B2 (en) 1994-07-07 1998-09-17 Geron Corporation Mammalian telomerase
JPH10509447A (ja) 1994-11-07 1998-09-14 ハイブライドン インコーポレイテッド ３ｈ−１，２−ベンゾジチオール−３−１，１−ジオキシドを用いた▲上３５▼ｓ−標識オリゴヌクレオチドの合成
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
AU2002245717A1 (en) * 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
CN100393209C (zh) 2003-09-09 2008-06-11 杰龙公司 用于端粒酶抑制的改性寡核苷酸
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
EP1812598A1 (en) * 2004-10-18 2007-08-01 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
SI2898887T1 (sl) 2006-10-30 2019-01-31 Geron Corporation Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Similar Documents

Publication Publication Date Title
JP2021182946A5 (https=)
US6833361B2 (en) Nucleosides having bicyclic sugar moiety
US8569478B2 (en) Modified 4′-nucleosides as antiviral agents
US6403566B1 (en) Nucleosides having bicyclic sugar moiety
Watanabe et al. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides
US8470987B2 (en) Protective group for synthesis of RNA and derivative
JP2017514479A5 (https=)
KR100279953B1 (ko) 항-b형 간염 바이러스제 및 항-사람 면역결핍 바이러스제로서의 l-2',3'-디데옥시 누클레오시드 유사체
CA2584367A1 (en) Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
EP1572705A2 (en) Sugar modified nucleosides as viral replication inhibitors
JP2018538302A5 (https=)
JP6671355B2 (ja) 呼吸器多核体ウイルスのｒｎａ複製の阻害剤としての４’‐ビニル置換ヌクレオシド誘導体
FI94763B (fi) Menetelmä uusien 2'-halogeenimetylideeni-, 2'-etenylideeni- ja 2'-etynyyliadenosiinijohdannaisten valmistamiseksi
WO2024077111A3 (en) Compositions, methods, and systems for detecting nucleotides
AU636678B2 (en) Nucleoside derivatives
US10087209B2 (en) Antiviral compounds, a process for their preparation, and their use for treating viral infections
JP2020537652A5 (https=)
Herdewijn et al. Nucleotides. Part. XXXII. Synthesis of 2′–5′ Connected oligonucleotides. Prodrugs for antiviral and antitumoral nucleosides
WO2004043402A2 (en) Modified nucleosides as antiviral agents
JP2001335592A (ja) ４’−ｃ−エチニルプリンヌクレオシド化合物
JP2001335593A (ja) ４’−ｃ−エチニルピリミジンヌクレオシド化合物
Chevrier et al. Synthesis of 5, 5-difluoro-5-phosphono-pent-2-en-1-yl nucleosides as potential antiviral agents
MX2008004079A (en) Modified 4'-nucleosides as antiviral agents
Lashley Investigations into 5ꞌ-Extended 3-Deazaaristeromycin Derivatives
CZ20004181A3 (cs) Sloučenina zahrnující nukleosid s 2',4'-můstkem a oligonukleotid od ní odvozený